What is clinical trial supply and logistics, and when do you need it?
Clinical trial supply and logistics is the chain of work that gets your investigational medicinal product (IMP) from a finished, released batch into a patient's hands at a trial site, and then accounts for every unit afterward. It covers clinical packaging and labeling, blinding and randomization, building the interactive response technology (IRT, also called RTSM) that assigns kits to subjects, distributing product through depots to sites, keeping cold-chain product in range the whole way, and handling returns, reconciliation, and destruction at the end. It is the operational layer that sits between your drug product and your clinical sites.
You need this work the moment a study is funded and the protocol is close to final, well before first-patient-in. Supply is almost always on the critical path for study startup, because labeled, randomized, released product has to be sitting at activated sites before you can enroll. A common scheduling mistake is treating supply as something to arrange after the sites are picked. In practice you scope it backward from your target site-activation date, then add lead time for label translations, QP release in Europe, import licenses, and depot setup.
The exact shape of the work shifts with your trial. A small Phase 1 single-site study in one country might need little more than labeling, a simple randomization, and courier delivery. A global Phase 3 across dozens of countries needs a depot network, country-specific labeling in many languages, comparator and rescue-medication sourcing, customs and import handling, temperature-controlled distribution with monitored excursions, and an IRT system that manages resupply triggers so no site runs out and you do not over-produce expensive drug. Both are clinical trial supply; the operational weight is completely different.
What does a clinical trial supply and logistics vendor actually do?
The label "clinical supply" hides a stack of distinct functions, and a given vendor rarely does all of them equally well. Some are GMP packaging and labeling houses; some are pure logistics and depot operators; some are IRT software vendors; some are comparator sourcing specialists. Understanding which piece you are buying is half the diligence, because the strongest packaging CDMO is not automatically the right distribution partner, and an IRT platform is a separate purchase from the physical supply.
Most clinical supply scopes draw on the following:
- Clinical packaging and labeling: primary and secondary packaging of IMP, booklet and single-panel labels, multi-language and country-specific label translation, and just-in-time labeling so kits can be re-destined late without re-manufacture.
- Blinding and randomization support: over-encapsulation or matched placebo handling, blind-protecting label design, and the randomization schedule that the IRT enforces at the patient level.
- IRT / RTSM: the interactive response system that randomizes subjects, assigns kits, triggers automatic resupply to keep sites stocked, manages expiry and re-dating, and gives the sponsor real-time inventory visibility across the whole study.
- Comparator and ancillary sourcing: procuring marketed comparator drug, standard-of-care background therapy, and rescue medication, with documented provenance and chain of custody, plus ancillary clinical supplies and devices.
- Cold-chain distribution and depot management: a network of regional depots, temperature-controlled shipping (2 to 8 C, frozen, or ambient), continuous temperature monitoring, excursion management, and customs, import, and qualified-person release where required.
- Returns, reconciliation, and destruction: collecting unused and expired product from sites, reconciling drug accountability against what was dispensed, and documenting GMP-compliant destruction for the trial master file.
How do you choose a clinical trial supply and logistics CRO or CDMO?
Score two or three vendors against the same written scope, the geographies you will actually run in, and your product's storage and blinding requirements, rather than chasing the lowest packaging price. For clinical supply, the cost of a stockout that pauses enrollment, or a temperature excursion that quarantines a batch, dwarfs any saving on unit packaging. Match the vendor to the trial you are running before you compare quotes.
- Quality and GxP status: confirm GMP packaging and labeling, good distribution practice (GDP) for the logistics legs, qualified-person (QP) release capability for the EU, and a clean regulatory inspection history. Ask to see the most recent audit findings.
- Capacity and lead time: get realistic lead times for labeling, QP release, and depot setup, and confirm slot availability against your site-activation date. Booking and label translation lead time, not the science, is usually what slips startup.
- Modality and product fit: cold-chain and frozen handling for biologics, cell and gene therapy, and mRNA; controlled-substance handling where relevant; and experience with your dosage form, whether that is a vial, a prefilled syringe, an oral solid, or a patient-specific autologous product.
- Region and regulatory track record: depot coverage and import or export experience in every country on your study, including customs, local labeling rules, and any country-specific release requirements. A vendor strong in the US and EU may be thin where you actually need sites.
- Data quality and inventory visibility: a validated IRT that gives real-time drug accountability, automated resupply triggers, expiry and re-dating management, and clean audit trails that hold up in a GCP inspection and reconcile against the trial master file.
- IP and confidentiality: a signed CDA before disclosure, protected handling of your protocol and blinding scheme, and clear terms on who controls the randomization data and how blind integrity is maintained across packaging, distribution, and any unblinding.